Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline
Susanna Yee-Shan Cheng, William Kenneth Evans, Denise Stys‐Norman et al. · Journal of Thoracic Oncology · 2007
Cited by 94 works. doi:10.1097/01.jto.0000263720.15062.51
Authors
References
- A Southwest Oncology Group study
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
- The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.
- Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer
- Small-cell lung cancer: treatment progress and prospects.
- Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study
- O-157 Survival benefit of oral topotecan plus supportive care versus supportive care alone in relapsed, resistant SCLC
- Topotecan in the Treatment of Relapsed Small Cell Lung Cancer Patients with Poor Performance Status
- A phase II randomised trial comparing the cisplatin–etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer